57 results about "Artemisinic acid" patented technology

An artemisinic acid derivative includes: a water-soluble organic salt formed by a reaction of artemisinic acid or dihydroartemisinic acid with a small-molecule basic organic compound, or a water-soluble complex formed by a reaction of artemisinic acid or dihydroartemisinic acid with a small molecule peptide, or a water-soluble salt formed by a reaction of artemisinic acid or dihydroartemisinic acid with a basic metal compound. The artemisinic acid derivative provided by the present application solves the problem of difficulty in dissolving the artemisinic acid and the dihydroartemisinic acid in water, and combines whitening, anti-inflammatory, and anti-tumor biological activities, thus having a good research and development prospect.

Disclosed is a composition having whitening efficacy. The composition comprises artemisinic acid and further comprises nicotinamide and / or glutathione. The compounding of artemisinic acid and nicotinamide and / or glutathione inhibits, by means of different pathways or mechanisms, the generation or transfer of melanin comprehensively and from multiple angles. The composition can significantly inhibit tyrosinase activity and inhibit the production of melanin, and the active ingredients complement each other and achieve synergistic efficacy. In addition, the composition can also enhance the water solubility of artemisinic acid and reduce the local irritation toxicity caused by the insolubility of artemisinic acid, thereby making the artemisinic acid have good water solubility and low local irritation toxicity while achieving the whitening effect, and promoting deep absorption by the skin.

The application provides a pharmaceutical composition for treating oviduct inflammation and peritonitis of laying hens and a preparation method thereof, and belongs to the technical field of veterinary drugs. The pharmaceutical composition is obtained by mixing 2-10 parts of artemisinic acid, 1-10 parts of marrubiin hydrochloride, 1-10 parts of sodium salicylate, 0.001-0.005 parts of imipenem / cilastatin sodium and auxiliary materials. The pharmaceutical composition can treat oviduct inflammation, peritonitis and intestinal secondary infection of laying hens through anti-pathogenic microorganism infection and anti-inflammatory pathways, and significantly improves the production performance of laying hens. After the chickens are medicated, the effect is fast, the egg production rate is obviously increased, and the substandard egg rate is obviously decreased. The oviduct inflammation and peritonitis of laying hens over 300 days old can be effectively solved, the clinical use is safe and reliable, the meat and egg food quality and safety can be improved, and it is particularly important for large-scale laying hen farms.